This grant application seeks continued support for the Pediatric Oncology Group (POG) activities of the Southwestern Medical School Consortium, which consists of the University of Texas Southwestern Medical School (Dallas) and Cook-Fort Worth Children's Medical Center (Fort Worth). Since joining POG in 1981, this partnership of children's cancer treatment and research centers in North Texas has grown to become the Group's largest contributing member with regard to patients enrolled annually on therapeutic studies (over 100 per year). Moreover, during the current grant cycle, investigators from Southwestern have risen to positions of leadership on major Group committees, including the Executive Committee, New Agents and Pharmacology Committee, and Lymphoid Relapse Committee. Southwestern investigators have also served and are serving as study coordinators of over 20 POG treatment protocols, including studies of acute lymphoid leukemia (ALL) in first marrow relapse, advanced stage undifferentiated lymphoma, B-cell ALL, advanced stage large cell lymphoma, neuroblastoma, bone marrow transplantation, and a number of Phase II studies. Moreover, investigators in the Consortium have has prominent roles within the Group in the areas of data management, protocol development, pharmacologic monitoring, and supportive care. Results of pilot studies conducted at Southwestern, in particular the Dallas/Fort Worth (DFW) protocol for non-T, non-B ALL, have been shared with the Group, and the data have been used in the construct of the next generation of POG protocols. We now affirm a continued commitment to POG research during the next 5 years. This grant proposal describes the personnel and facilities in the Consortium centers (including for the first time Scott & White Clinic), involved in numerous cancer research arenas, within and outside POG. Specifically, during 1991-1995 we aim to advance POG research by: 1) actively enrolling as many patients as possible on POG treatment, laboratory classification, and epidemiologic protocols; 2) collecting, recording, and submitting all necessary research data accurately and in a timely fashion on order that our protocol entries continue to receive a high rate of evaluability; 3) making scientific contributions to the Group through active participation on key committees, as disease committee chairmen, and providing service as protocol coordinators and consultants to the Group's leaders; and 4) continuing to conduct innovative in-house pilot studies to be used later by the Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA033625-09
Application #
3557339
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1983-01-01
Project End
1995-12-31
Budget Start
1991-04-15
Budget End
1991-12-31
Support Year
9
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Wacker, Pierre; Land, Vita J; Camitta, Bruce M et al. (2007) Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol 29:627-32
Whitehead, V M; Shuster, J J; Vuchich, M J et al. (2005) Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 19:533-6
Hirschman, Barbara A; Pollock, Brad H; Tomlinson, Gail E (2005) The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. J Pediatr 147:263-6
Tomlinson, Gail E; Douglass, Edwin C; Pollock, Brad H et al. (2005) Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21. Genes Chromosomes Cancer 44:177-84
Ravindranath, Y; Chang, M; Steuber, C P et al. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-16
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Goorin, Allen M; Schwartzentruber, Douglas J; Devidas, Meenakshi et al. (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-80
Blanco, Javier G; Edick, Mathew J; Hancock, Michael L et al. (2002) Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 12:605-11
Leavey, Patrick J; Mantadakis, Elpis; Maale, Gerhard (2002) Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma. Pediatr Hematol Oncol 19:483-9
Lacayo, N J; Lum, B L; Becton, D L et al. (2002) Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 16:920-7

Showing the most recent 10 out of 50 publications